According to the Zhitong Finance App, *ST Eye Medicine (600671.SH) announced that the company recently received the “Decision on Issuing Warning Letter Measures against Hangzhou Tianmusan Pharmaceutical Co., Ltd. and related responsible persons” (“Warning Letter”) issued by the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission (“Zhejiang Securities Regulatory Bureau”).

According to reports, the Zhejiang Securities Regulatory Bureau discovered that the company had the following problems during supervision: 1. The company's reporting of projects under construction in 2020-2022 was incorrect and there was a problem of underrecording depreciation. 2. The company did not promptly disclose the bank account freeze situation. 3. The company did not promptly disclose the progress of the bankruptcy and liquidation of the holding subsidiary Zhejiang Tianmu Biotechnology Co., Ltd. (“Tianmu Biotech”). 4. The disclosure of information relating to the company's performance forecast is inaccurate. 5. The materials of the company's board of directors were incomplete, and some directors did not sign on the meeting resolution signing page.

According to the announcement, the company's above issues violate relevant regulations; Li Feng, the company's chairman, then financial director and secretary of the board of directors, and Liu Bo, general manager, bear the main responsibility for the above irregularities. According to regulations, the Zhejiang Securities Regulatory Bureau decided to take supervisory and administrative measures by issuing separate warning letters against the company, Li Feng, and Liu Bo, and record them in the securities and futures market integrity files.